ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE
The incidence of chronic kidney disease (CKD) in Type 2 Diabetes Mellitus patients accounts for 34,6–40% of cases. The importance of glycemic control for the prevention of kidney damage and progression of nephropathy in T2DM patients is proven in numerous studies. The presence of CKD significantly...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-07-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1936 |
| Summary: | The incidence of chronic kidney disease (CKD) in Type 2 Diabetes Mellitus patients accounts for 34,6–40% of cases. The importance of glycemic control for the prevention of kidney damage and progression of nephropathy in T2DM patients is proven in numerous studies. The presence of CKD significantly limits the choice of antidiabetic drugs and requires changes in dosages. Sitagliptin-DPP-4 inhibitor is approved for use at any stage of CKD. Clinical studies involving Sitagliptin provide a powerful base demonstrating the effectiveness and safety of the drug in CKD. The article presents the data of clinical and experimental studies indicating the protective role of Sitagliptin in the development of renal damage. The animal experiments revealed that the suppression of the activity of DPP-4 by Sitagliptin in kidneys leads to regression of renal damage, with reduced markers of inflammation and endothelial dysfunction. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |